GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Karolinska Development AB (OTCPK:KDEVF) » Definitions » EV-to-EBITDA

Karolinska Development AB (Karolinska Development AB) EV-to-EBITDA : 44.38 (As of Apr. 30, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Karolinska Development AB EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Karolinska Development AB's enterprise value is $30.40 Mil. Karolinska Development AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $0.69 Mil. Therefore, Karolinska Development AB's EV-to-EBITDA for today is 44.38.

The historical rank and industry rank for Karolinska Development AB's EV-to-EBITDA or its related term are showing as below:

KDEVF' s EV-to-EBITDA Range Over the Past 10 Years
Min: -8.25   Med: -1.12   Max: 63.13
Current: 53.53

During the past 13 years, the highest EV-to-EBITDA of Karolinska Development AB was 63.13. The lowest was -8.25. And the median was -1.12.

KDEVF's EV-to-EBITDA is ranked worse than
88.27% of 469 companies
in the Biotechnology industry
Industry Median: 9.09 vs KDEVF: 53.53

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-30), Karolinska Development AB's stock price is $0.2576. Karolinska Development AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.001. Therefore, Karolinska Development AB's PE Ratio for today is 257.60.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Karolinska Development AB EV-to-EBITDA Historical Data

The historical data trend for Karolinska Development AB's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Karolinska Development AB EV-to-EBITDA Chart

Karolinska Development AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.77 -1.37 5.43 -3.02 59.12

Karolinska Development AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.02 -3.63 -3.59 -3.56 59.12

Competitive Comparison of Karolinska Development AB's EV-to-EBITDA

For the Biotechnology subindustry, Karolinska Development AB's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Karolinska Development AB's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Karolinska Development AB's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Karolinska Development AB's EV-to-EBITDA falls into.



Karolinska Development AB EV-to-EBITDA Calculation

Karolinska Development AB's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=30.400/0.685
=44.38

Karolinska Development AB's current Enterprise Value is $30.40 Mil.
Karolinska Development AB's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Karolinska Development AB  (OTCPK:KDEVF) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Karolinska Development AB's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.2576/0.001
=257.60

Karolinska Development AB's share price for today is $0.2576.
Karolinska Development AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.001.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Karolinska Development AB EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Karolinska Development AB's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Karolinska Development AB (Karolinska Development AB) Business Description

Traded in Other Exchanges
Address
TomtebodavAgen 23 A, Solna, SWE, SE-171 65
Karolinska Development AB is a life science investment company. It is focused on identifying breakthrough medical innovations in the Nordic region. It selects commercially attractive medical innovations, develops innovations to the stage where the return on investment can be achieved and commercializes the innovations through the sale of companies or out-licensing of products. The company focused on profiles namely Aprea Therapeutics; Modus Therapeutics; BioArctic; Umecrine Cognition; and OssDsign.